Appendix JReferences for Appendixes

Publication Details

1.
Alcala L, Reigadas E, Marin M, et al. Comparison of GenomEra C. difficile and Xpert C. difficile as confirmatory tests in a multistep algorithm for diagnosis of Clostridium difficile infection. J Clin Microbiol. 2015 Jan;53(1):332–5. [PMC free article: PMC4290947] [PubMed: 25392360]
2.
Barkin JA, Nandi N, Miller N, et al. Superiority of the DNA amplification assay for the diagnosis of C. difficile infection: a clinical comparison of fecal tests. Dig Dis Sci. 2012 Oct;57(10):2592–9. [PubMed: 22576711]
3.
Bruins MJ, Verbeek E, Wallinga JA, et al. Evaluation of three enzyme immunoassays and a loop-mediated isothermal amplification test for the laboratory diagnosis of Clostridium difficile infection. Eur J Clin Microbiol Infect Dis. 2012 Nov;31(11):3035–9. [PubMed: 22706512]
4.
Buchan BW, Mackey TL, Daly JA, et al. Multicenter clinical evaluation of the portrait toxigenic C. difficile assay for detection of toxigenic Clostridium difficile strains in clinical stool specimens. J Clin Microbiol. 2012 Dec;50(12):3932–6. [PMC free article: PMC3502949] [PubMed: 23015667]
5.
Calderaro A, Buttrini M, Martinelli M, et al. Comparative analysis of different methods to detect Clostridium difficile infection. New Microbiol. 2013 Jan;36(1):57–63. [PubMed: 23435816]
6.
Carroll KC, Buchan BW, Tan S, et al. Multicenter evaluation of the Verigene Clostridium difficile nucleic acid assay. J Clin Microbiol. 2013 Dec;51(12):4120–5. [PMC free article: PMC3838056] [PubMed: 24088862]
7.
Dalpke AH, Hofko M, Zorn M, et al. Evaluation of the fully automated BD MAX Cdiff and Xpert C. difficile assays for direct detection of Clostridium difficile in stool specimens. J Clin Microbiol. 2013 Jun;51(6):1906–8. [PMC free article: PMC3716071] [PubMed: 23515539]
8.
de Boer RF, Wijma JJ, Schuurman T, et al. Evaluation of a rapid molecular screening approach for the detection of toxigenic Clostridium difficile in general and subsequent identification of the tcdC 117 mutation in human stools. J Microbiol Methods. 2010 Oct;83(1):59–65. [PubMed: 20674616]
9.
de Jong E, de Jong AS, Bartels CJ, et al. Clinical and laboratory evaluation of a real-time PCR for Clostridium difficile toxin A and B genes. Eur J Clin Microbiol Infect Dis. 2012 Sep;31(9):2219–25. [PMC free article: PMC3418502] [PubMed: 22327373]
10.
Eckert C, Holscher E, Petit A, et al. Molecular test based on isothermal helicase-dependent amplification for detection of the Clostridium difficile toxin A gene. J Clin Microbiol. 2014 Jul;52(7):2386–9. [PMC free article: PMC4097749] [PubMed: 24759714]
11.
Eigner U, Fenner I, Veldenzer A, et al. Evaluation of six PCR assays in combination with patient related data for the diagnosis of Clostridium difficile-associated infections. Clin Lab. 2014;60(8):1343–50. [PubMed: 25185420]
12.
Herrera-Caceres JO, Camacho-Ortiz A, Galindo-Fraga A, et al. Concordance between two enzyme immunoassays for the detection of Clostridium difficile toxins. Arch Med Res. 2010 Feb;41(2):92–6. [PubMed: 20470937]
13.
Hirvonen JJ, Mentula S, Kaukoranta SS. Evaluation of a new automated homogeneous PCR assay, GenomEra C. difficile, for rapid detection of Toxigenic Clostridium difficile in fecal specimens. J Clin Microbiol. 2013 Sep;51(9):2908–12. [PMC free article: PMC3754623] [PubMed: 23804386]
14.
Hoegh AM, Nielsen JB, Lester A, et al. A multiplex, internally controlled real-time PCR assay for detection of toxigenic Clostridium difficile and identification of hypervirulent strain 027/ST-1. Eur J Clin Microbiol Infect Dis. 2012 Jun;31(6):1073–9. [PubMed: 21938539]
15.
Humphries RM, Uslan DZ, Rubin Z. Performance of Clostridium difficile toxin enzyme immunoassay and nucleic acid amplification tests stratified by patient disease severity. J Clin Microbiol. 2013 Mar;51(3):869–73. [PMC free article: PMC3592059] [PubMed: 23269736]
16.
Jensen MB, Olsen KE, Nielsen XC, et al. Diagnosis of Clostridium difficile: real-time PCR detection of toxin genes in faecal samples is more sensitive compared to toxigenic culture. Eur J Clin Microbiol Infect Dis. 2015 Apr;34(4):727–36. [PubMed: 25421216]
17.
Kim H, Jeong SH, Kim M, et al. Detection of Clostridium difficile toxin A/B genes by multiplex real-time PCR for the diagnosis of C. difficile infection. J Med Microbiol. 2012 Feb;61(Pt 2):274–7. [PubMed: 21959205]
18.
Knetsch CW, Bakker D, de Boer RF, et al. Comparison of real-time PCR techniques to cytotoxigenic culture methods for diagnosing Clostridium difficile infection. J Clin Microbiol. 2011 Jan;49(1):227–31. [PMC free article: PMC3020438] [PubMed: 20980562]
19.
Lalande V, Barrault L, Wadel S, et al. Evaluation of a loop-mediated isothermal amplification assay for diagnosis of Clostridium difficile infections. J Clin Microbiol. 2011 Jul;49(7):2714–6. [PMC free article: PMC3147856] [PubMed: 21525213]
20.
Landry ML, Ferguson D, Topal J. Comparison of Simplexa universal direct PCR with cytotoxicity assay for diagnosis of Clostridium difficile infection: performance, cost, and correlation with disease. J Clin Microbiol. 2014 Jan;52(1):275–80. [PMC free article: PMC3911468] [PubMed: 24226924]
21.
Le Guern R, Herwegh S, Grandbastien B, et al. Evaluation of a new molecular test, the BD Max Cdiff, for detection of toxigenic Clostridium difficile in fecal samples. J Clin Microbiol. 2012 Sep;50(9):3089–90. [PMC free article: PMC3421774] [PubMed: 22760042]
22.
Leitner E, Einetter M, Grisold AJ, et al. Evaluation of the BD MAX Cdiff assay for the detection of the toxin B gene of Clostridium difficile out of faecal specimens. Diagn Microbiol Infect Dis. 2013 Jul;76(3):390–1. [PubMed: 23602785]
23.
Mattner F, Winterfeld I, Mattner L. Diagnosing toxigenic Clostridium difficile: new confidence bounds show culturing increases sensitivity of the toxin A/B enzyme immunoassay and refute gold standards. Scand J Infect Dis. 2012 Aug;44(8):578–85. [PubMed: 22404319]
24.
Noren T, Alriksson I, Andersson J, et al. Rapid and sensitive loop-mediated isothermal amplification test for Clostridium difficile detection challenges cytotoxin B cell test and culture as gold standard. J Clin Microbiol. 2011 Feb;49(2):710–1. [PMC free article: PMC3043499] [PubMed: 21106782]
25.
Noren T, Unemo M, Magnusson C, et al. Evaluation of the rapid loop-mediated isothermal amplification assay Illumigene for diagnosis of Clostridium difficile in an outbreak situation. Apmis. 2014 Feb;122(2):155–60. [PubMed: 23758095]
26.
Planche TD, Davies KA, Coen PG, et al. Differences in outcome according to Clostridium difficile testing method: a prospective multicentre diagnostic validation study of C difficile infection. The Lancet infectious diseases. 2013 Nov;13(11):936–45. [PMC free article: PMC3822406] [PubMed: 24007915]
27.
Putsathit P, Morgan J, Bradford D, et al. Evaluation of the BD Max Cdiff assay for the detection of toxigenic Clostridium difficile in human stool specimens. Pathology. 2015 Feb;47(2):165–8. [PubMed: 25551308]
28.
Qutub MO, AlBaz N, Hawken P, et al. Comparison between the two-step and the three-step algorithms for the detection of toxigenic Clostridium difficile. Indian J. 2011 Jul-Sep;29(3):293–6. [PubMed: 21860113]
29.
Reller ME, Alcabasa RC, Lema CA, et al. Comparison of two rapid assays for Clostridium difficile Common antigen and a C difficile toxin A/B assay with the cell culture neutralization assay. Am J Clin Pathol. 2010 Jan;133(1):107–9. [PubMed: 20023265]
30.
Rene P, Frenette CP, Schiller I, et al. Comparison of eight commercial enzyme immunoassays for the detection of Clostridium difficile from stool samples and effect of strain type. Diagn Microbiol Infect Dis. 2012 May;73(1):94–6. [PubMed: 22424900]
31.
Shin S, Kim M, Kim M, et al. Evaluation of the Xpert Clostridium difficile assay for the diagnosis of Clostridium difficile infection. Ann Lab Med. 2012 Sep;32(5):355–8. [PMC free article: PMC3427823] [PubMed: 22950071]
32.
Shin BM, Mun SJ, Yoo SJ, et al. Comparison of BD GeneOhm Cdiff and Seegene Seeplex ACE PCR assays using toxigenic Clostridium difficile culture for direct detection of tcdB from stool specimens. J Clin Microbiol. 2012 Nov;50(11):3765–7. [PMC free article: PMC3486254] [PubMed: 22952270]
33.
Strachan AJ, Evans NE, Williams OM, et al. Comparison of a frozen human foreskin fibroblast cell assay to an enzyme immunoassay and toxigenic culture for the detection of toxigenic Clostridium difficile. Diagn Microbiol Infect Dis. 2013 Jan;75(1):42–5. [PMC free article: PMC3525856] [PubMed: 23107315]
34.
Viala C, Le Monnier A, Maataoui N, et al. Comparison of commercial molecular assays for toxigenic Clostridium difficile detection in stools: BD GeneOhm Cdiff, XPert C. difficile and illumigene C. difficile. J Microbiol Methods. 2012 Aug;90(2):83–5. [PubMed: 22565213]
35.
Walkty A, Lagace-Wiens PR, Manickam K, et al. Evaluation of an algorithmic approach in comparison with the Illumigene assay for laboratory diagnosis of Clostridium difficile infection. J Clin Microbiol. 2013 Apr;51(4):1152–7. [PMC free article: PMC3666773] [PubMed: 23363829]
36.
Zidaric V, Kevorkijan BK, Oresic N, et al. Comparison of two commercial molecular tests for the detection of Clostridium difficile in the routine diagnostic laboratory. J Med Microbiol. 2011 Aug;60(Pt 8):1131–6. [PubMed: 21372187]
37.
Johnson S, Louie TJ, Gerding DN, et al. Vancomycin, metronidazole, or tolevamer for Clostridium difficile infection: results from two multinational, randomized, controlled trials. Clinical Infectious Diseases. 2014;59(3):345–54. [PubMed: 24799326]
38.
Cornely OA, Crook DW, Esposito R, et al. Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial. The Lancet infectious diseases. 2012 Apr;12(4):281–9. [PubMed: 22321770]
39.
Wenisch JM, Schmid D, Kuo HW, et al. Prospective observational study comparing three different treatment regimes in patients with Clostridium difficile infection. Antimicrob Agents Chemother. 2012 Apr;56(4):1974–8. [PMC free article: PMC3318337] [PubMed: 22252830]
40.
Louie TJ, Miller MA, Mullane KM, et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. New England Journal of Medicine. 2011 Feb 3;364(5):422–31. [PubMed: 21288078]
41.
Zar FA, Bakkanagari SR, Moorthi KM, et al. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clinical Infectious Diseases. 2007 Aug 1;45(3):302–7. [PubMed: 17599306]
42.
Wenisch C, Parschalk B, Hasenhundl M, et al. Comparison of vancomycin, teicoplanin, metronidazole, and fusidic acid for the treatment of Clostridium difficile-associated diarrhea. Clinical Infectious Diseases. 1996 May;22(5):813–8. [PubMed: 8722937]
43.
Teasley DG, Gerding DN, Olson MM, et al. Prospective randomised trial of metronidazole versus vancomycin for Clostridium-difficile-associated diarrhoea and colitis. Lancet. 1983 Nov 5;2(8358):1043–6. [PubMed: 6138597]
44.
Cammarota G, Masucci L, Ianiro G, et al. Randomised clinical trial: faecal microbiota transplantation by colonoscopy vs. vancomycin for the treatment of recurrent Clostridium difficile infection. Aliment Pharmacol Ther. 2015 May;41(9):835–43. [PubMed: 25728808]
45.
Satokari R, Mattila E, Kainulainen V, et al. Simple faecal preparation and efficacy of frozen inoculum in faecal microbiota transplantation for recurrent Clostridium difficile infection--an observational cohort study. Aliment Pharmacol Ther. 2015 Jan;41(1):46–53. [PubMed: 25355279]
46.
Zainah H, Hassan M, Shiekh-Sroujieh L, et al. Intestinal microbiota transplantation, a simple and effective treatment for severe and refractory Clostridium difficile infection. Dig Dis Sci. 2015 Jan;60(1):181–5. [PubMed: 25052150]
47.
Dutta SK, Girotra M, Garg S, et al. Efficacy of combined jejunal and colonic fecal microbiota transplantation for recurrent Clostridium difficile infection. Clin Gastroenterol Hepatol. 2014. PMID. [PubMed: 24440222]
48.
Khan AM, Sofi AA, Ahmad U, et al. Efficacy and safety of, and patient satisfaction with, colonoscopic-administered fecal microbiota transplantation in relapsing and refractory community- and hospital-acquired Clostridium difficile infection. Can J Gastroenterol Hepatol. 2014;28(8):434–8. PMID. [PMC free article: PMC4210234] [PubMed: 25014180]
49.
Lee CH, Belanger JE, Kassam Z, et al. The outcome and long-term follow-up of 94 patients with recurrent and refractory Clostridium difficile infection using single to multiple fecal microbiota transplantation via retention enema. Eur J Clin Microbiol Infect Dis. 2014 Aug;33(8):1425–8. [PubMed: 24627239]
50.
Ray A, Smith R, Breaux J. Fecal microbiota transplantation for clostridium difficile infection: The ochsner experience. Ochsner Journal. 2014 Dec 01;14(4):538–44. [PMC free article: PMC4295730] [PubMed: 25598718]
51.
Seekatz AM, Aas J, Gessert CE, et al. Recovery of the gut microbiome following fecal microbiota transplantation. mBio. 2014;5(3):e00893–14. [PMC free article: PMC4068257] [PubMed: 24939885]
52.
Weingarden AR, Chen C, Bobr A, et al. Microbiota transplantation restores normal fecal bile acid composition in recurrent Clostridium difficile infection. Am J Physiol Gastrointest Liver Physiol. 2014 Feb 15;306(4):G310–9. [PMC free article: PMC3920123] [PubMed: 24284963]
53.
Youngster I, Russell GH, Pindar C, et al. Oral, capsulized, frozen fecal microbiota transplantation for relapsing Clostridium difficile infection. JAMA. 2014;312(17):1772–8. [PubMed: 25322359]
54.
Youngster I, Sauk J, Pindar C, et al. Fecal microbiota transplant for relapsing Clostridium difficle infection using a frozen inoculum from unrelated donors: a randomized, open-label, controlled pilot study. Clin Infect Dis. 2014;58(11):1515–22. [PMC free article: PMC4017893] [PubMed: 24762631]
55.
Emanuelsson F, Claesson BE, Ljungstrom L, et al. Faecal microbiota transplantation and bacteriotherapy for recurrent Clostridium difficile infection: a retrospective evaluation of 31 patients. Scand J Infect Dis. 2014 Feb;46(2):89–97. [PubMed: 24354958]
56.
Patel NC, Griesbach CL, DiBaise JK, et al. Fecal microbiota transplant for recurrent Clostridium difficile infection: Mayo Clinic in Arizona experience. Mayo Clin Proc. 2013 Aug;88(8):799–805. [PubMed: 23910407]
57.
Pathak R, Enuh HA, Patel A, et al. Treatment of relapsing Clostridium difficile infection using fecal microbiota transplantation. Clin Exp Gastroenterol. 2014;7:1–6. PMID. [PMC free article: PMC3881092] [PubMed: 24421645]
58.
Rubin TA, Gessert CE, Aas J, et al. Fecal microbiome transplantation for recurrent Clostridium difficile infection: report on a case series. Anaerobe. 2013 Feb;19:22–6. [PubMed: 23182843]
59.
van Nood E, Vrieze A, Nieuwdorp M, et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. New England Journal of Medicine. 2013 Jan 31;368(5):407–15. [PubMed: 23323867]
60.
Hamilton MJ, Weingarden AR, Sadowsky MJ, et al. Standardized frozen preparation for transplantation of fecal microbiota for recurrent Clostridium difficile infection. American Journal of Gastroenterology. 2012 May;107(5):761–7. [PubMed: 22290405]
61.
Jorup-Ronstrom C, Hakanson A, Sandell S, et al. Fecal transplant against relapsing Clostridium difficile-associated diarrhea in 32 patients. Scand J Gastroenterol. 2012 May;47(5):548–52. [PubMed: 22468996]
62.
Kelly CR, de Leon L, Jasutkar N. Fecal microbiota transplantation for relapsing Clostridium difficile infection in 26 patients: methodology and results. Journal of Clinical Gastroenterology. 2012 Feb;46(2):145–9. [PubMed: 22157239]
63.
Mattila E, Uusitalo-Seppala R, Wuorela M, et al. Fecal transplantation, through colonoscopy, is effective therapy for recurrent Clostridium difficile infection. Gastroenterology. 2012 Mar;142(3):490–6. [PubMed: 22155369]
64.
Mellow MH, Kanatzar A. Colonoscopic fecal bacteriotherapy in the treatment of recurrent Clostridium difficile infection--results and follow-up. J Okla State Med Assoc. 2011 Mar;104(3):89–91. [PubMed: 21608450]
65.
Garborg K, Waagsbo B, Stallemo A, et al. Results of faecal donor instillation therapy for recurrent Clostridium difficile-associated diarrhoea. Scand J Infect Dis. 2010 Dec;42(11-12):857–61. [PubMed: 20662620]
66.
Aas J, Gessert CE, Bakken JS. Recurrent Clostridium difficile colitis: case series involving 18 patients treated with donor stool administered via a nasogastric tube. Clinical Infectious Diseases. 2003 Mar 1;36(5):580–5. [PubMed: 12594638]
67.
Rohlke F, Surawicz C, Stollman N. Fecal flora reconstitution for recurrent clostridium difficile infection: results and methodology. Journal of Clinical Gastroenterology. 2010;44(8):567–70. PMID. [PubMed: 20485184]
68.
Yoon S, Brandt L. Treatment of refractory/recurrent C. difficile-associated disease by donated stool transplanted via colonoscopy: a case series of 12 patients. Journal of Clinical Gastroenterology. 2010;44(8):562–6. [PubMed: 20463588]
69.
MacConnachie AA, Fox R, Kennedy DR, et al. Faecal transplant for recurrent Clostridium difficile-associated diarrhoea: a UK case series. Qjm. 2009 Nov;102(11):781–4. [PubMed: 19726581]
70.
Ouwehand AC, DongLian C, Weijian X, et al. Probiotics reduce symptoms of antibiotic use in a hospital setting: a randomized dose response study. Vaccine. 2014 Jan 16;32(4):458–63. [PubMed: 24291194]
71.
Allen SJ, Wareham K, Wang D, et al. Lactobacilli and bifidobacteria in the prevention of antibiotic-associated diarrhoea and Clostridium difficile diarrhoea in older inpatients (PLACIDE): a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2013 Oct 12;382(9900):1249–57. [PubMed: 23932219]
72.
Selinger CP, Bell A, Cairns A, et al. Probiotic VSL#3 prevents antibiotic-associated diarrhoea in a double-blind, randomized, placebo-controlled clinical trial. Journal of Hospital Infection. 2013 Jun;84(2):159–65. [PubMed: 23618760]
73.
Pozzoni P, Riva A, Bellatorre AG, et al. Saccharomyces boulardii for the prevention of antibiotic-associated diarrhea in adult hospitalized patients: a single-center, randomized, double-blind, placebo-controlled trial. American Journal of Gastroenterology. 2012 Jun;107(6):922–31. [PubMed: 22472744]
74.
Gao XW, Mubasher M, Fang CY, et al. Dose-response efficacy of a proprietary probiotic formula of Lactobacillus acidophilus CL1285 and Lactobacillus casei LBC80R for antibiotic-associated diarrhea and Clostridium difficile-associated diarrhea prophylaxis in adult patients. American Journal of Gastroenterology. 2010 Jul;105(7):1636–41. [PubMed: 20145608]
75.
Lonnermark E, Friman V, Lappas G, et al. Intake of Lactobacillus plantarum reduces certain gastrointestinal symptoms during treatment with antibiotics. Journal of Clinical Gastroenterology. 2010 Feb;44(2):106–12. [PubMed: 19727002]
76.
Psaradellis E, Sampalis J, Rampakakis E, et al. Efficacy of BIO K+ CL1285® in the reduction of antibiotic-associated diarrhea–a placebo controlled double-blind randomized, multi-center study. Arch Med Sci. 2010;6(1):56–64. PMID. [PMC free article: PMC3278944] [PubMed: 22371721]
77.
Safdar N, Barigala R, Said A, et al. Feasibility and tolerability of probiotics for prevention of antibiotic-associated diarrhoea in hospitalized US military veterans. J Clin Pharm Ther. 2008 Dec;33(6):663–8. [PubMed: 19138244]
78.
Beausoleil M, Fortier N, Guenette S, et al. Effect of a fermented milk combining Lactobacillus acidophilus Cl1285 and Lactobacillus casei in the prevention of antibiotic-associated diarrhea: a randomized, double-blind, placebo-controlled trial. Can J Gastroenterol. 2007 Nov;21(11):732–6. [PMC free article: PMC2658588] [PubMed: 18026577]
79.
Duman DG, Bor S, Ozutemiz O, et al. Efficacy and safety of Saccharomyces boulardii in prevention of antibiotic-associated diarrhoea due to Helicobacterpylori eradication. Eur J Gastroenterol Hepatol. 2005 Dec;17(12):1357–61. [PubMed: 16292090]
80.
Maziade PJ, Andriessen JA, Pereira P, et al. Impact of adding prophylactic probiotics to a bundle of standard preventative measures for Clostridium difficile infections: enhanced and sustained decrease in the incidence and severity of infection at a community hospital. Curr Med Res Opin. 2013 Oct;29(10):1341–7. [PubMed: 23931498]
81.
Bakken JS. Staggered and tapered antibiotic withdrawal with administration of kefir for recurrent clostridium difficile infection. Clinical Infectious Diseases. 2014;59(6):858–61. [PubMed: 24917658]
82.
Hickson M, D'Souza AL, Muthu N, et al. Use of probiotic Lactobacillus preparation to prevent diarrhoea associated with antibiotics: randomised double blind placebo controlled trial. Bmj. 2007 Jul 14;335(7610):80. [PMC free article: PMC1914504] [PubMed: 17604300]
83.
Can M, Besirbellioglu BA, Avci IY, et al. Prophylactic Saccharomyces boulardii in the prevention of antibiotic-associated diarrhea: a prospective study. Medical Science Monitor. 2006 Apr;12(4):P19–22. [PubMed: 16572062]
84.
Plummer S, Weaver MA, Harris JC, et al. Clostridium difficile pilot study: effects of probiotic supplementation on the incidence of C. difficile diarrhoea. Int Microbiol. 2004 Mar;7(1):59–62. [PubMed: 15179608]
85.
Thomas MR, Litin SC, Osmon DR, et al. Lack of effect of Lactobacillus GG on antibiotic-associated diarrhea: a randomized, placebo-controlled trial. Mayo Clin Proc. 2001 Sep;76(9):883–9. [PubMed: 11560298]
86.
Lewis SJ, Potts LF, Barry RE. The lack of therapeutic effect of Saccharomyces boulardii in the prevention of antibiotic-related diarrhoea in elderly patients. Journal of Infection. 1998 Mar;36(2):171–4. [PubMed: 9570649]
87.
McFarland LV, Surawicz CM, Greenberg RN, et al. Prevention of beta-lactam-associated diarrhea by Saccharomyces boulardii compared with placebo. The American journal of gastroenterology. 1995 Mar;90(3):439–48. [PubMed: 7872284]
88.
Surawicz CM, Elmer GW, Speelman P, et al. Prevention of antibiotic-associated diarrhea by Saccharomyces boulardii: a prospective study. Gastroenterology. 1989 Apr;96(4):981–8. [PubMed: 2494098]
89.
Puri BK, Hakkarainen-Smith JS, Monro JA. The potential use of cholestyramine to reduce the risk of developing Clostridium difficile-associated diarrhoea in patients receiving long-term intravenous ceftriaxone. Med Hypotheses. 2015 Jan;84(1):78–80. [PubMed: 25497389]
90.
Garey KW, Ghantoji SS, Shah DN, et al. A randomized, double-blind, placebo-controlled pilot study to assess the ability of rifaximin to prevent recurrent diarrhoea in patients with Clostridium difficile infection. J Antimicrob Chemother. 2011 Dec;66(12):2850–5. [PubMed: 21948965]
91.
Laffan AM, McKenzie R, Forti J, et al. Lactoferrin for the prevention of post-antibiotic diarrhoea. J Health Popul Nutr. 2011 Dec;29(6):547–51. [PMC free article: PMC3259716] [PubMed: 22283027]
92.
Filice G, Drekonja D, Greer N, et al. Antimicrobial stewardship programs in inpatient settings: a systematic review. 2013 In: #09-009 V-Ep, ed. [PubMed: 25411666]
93.
Rupp ME, Cavalieri RJ, Lyden E, et al. Effect of hospital-wide chlorhexidine patient bathing on healthcare-associated infections. Infect Control Hosp Epidemiol. 2012 Nov;33(11):1094–100. [PubMed: 23041806]
94.
Noto MJ, Domenico HJ, Byrne DW, et al. Chlorhexidine bathing and health care-associated infections: a randomized clinical trial. JAMA. 2015 Jan 27;313(4):369–78. [PMC free article: PMC4383133] [PubMed: 25602496]
95.
Alfa MJ, Lo E, Olson N, et al. Use of a daily disinfectant cleaner instead of a daily cleaner reduced hospital-acquired infection rates. American journal of infection control. 2015 Feb;43(2):141–6. [PubMed: 25534117]
96.
Levin J, Riley LS, Parrish C, et al. The effect of portable pulsed xenon ultraviolet light after terminal cleaning on hospital-associated Clostridium difficile infection in a community hospital. American journal of infection control. 2013 Aug;41(8):746–8. [PubMed: 23685092]
97.
Manian FA, Griesnauer S, Bryant A. Implementation of hospital-wide enhanced terminal cleaning of targeted patient rooms and its impact on endemic Clostridium difficile infection rates. American journal of infection control. 2013 Jun;41(6):537–41. [PubMed: 23219675]
98.
Passaretti CL, Otter JA, Reich NG, et al. An evaluation of environmental decontamination with hydrogen peroxide vapor for reducing the risk of patient acquisition of multidrug-resistant organisms. Clinical Infectious Diseases. 2013 Jan;56(1):27–35. [PubMed: 23042972]
99.
Stone SP, Fuller C, Savage J, et al. Evaluation of the national Cleanyourhands campaign to reduce Staphylococcus aureus bacteraemia and Clostridium difficile infection in hospitals in England and Wales by improved hand hygiene: four year, prospective, ecological, interrupted time series study. Bmj. 2012;344:e3005. [PMC free article: PMC3343183] [PubMed: 22556101]
100.
DiDiodato G. Has improved hand hygiene compliance reduced the risk of hospital-acquired infections among hospitalized patients in Ontario? Analysis of publicly reported patient safety data from 2008 to 2011. Infect Control Hosp Epidemiol. 2013 Jun;34(6):605–10. [PubMed: 23651891]
101.
Bearman G, Rosato AE, Duane TM, et al. Trial of universal gloving with emollient-impregnated gloves to promote skin health and prevent the transmission of multidrug-resistant organisms in a surgical intensive care unit. Infect Control Hosp Epidemiol. 2010 May;31(5):491–7. [PubMed: 20350197]
102.
Brakovich B, Bonham E, VanBrackle L. War on the spore: Clostridium difficile disease among patients in a long-term acute care hospital. J Healthc Qual. 2013 May-Jun;35(3):15–21. [PubMed: 22304334]
103.
Bishop J, Parry MF, Hall T. Decreasing Clostridium difficile infections in surgery: impact of a practice bundle incorporating a resident rounding protocol. Conn Med. 2013 Feb;77(2):69–75. [PubMed: 23513633]
104.
Mermel LA, Jefferson J, Blanchard K, et al. Reducing Clostridium difficile incidence, colectomies, and mortality in the hospital setting: a successful multidisciplinary approach. Jt Comm J Qual Patient Saf. 2013 Jul;39(7):298–305. [PubMed: 23888639]
105.
Price J, Cheek E, Lippett S, et al. Impact of an intervention to control Clostridium difficile infection on hospital- and community-onset disease; an interrupted time series analysis. Clin Microbiol Infect. 2010 Aug;16(8):1297–302. [PubMed: 19832710]
106.
You E, Song H, Cho J, et al. Reduction in the incidence of hospital-acquired Clostridium difficile infection through infection control interventions other than the restriction of antimicrobial use. Int J Infect Dis. 2014 May;22:9–10. [PubMed: 24583565]
107.
Brandt LJ, Aroniadis OC, Mellow M, et al. Long-term follow-up of colonoscopic fecal microbiota transplant for recurrent Clostridium difficile infection. American Journal of Gastroenterology. 2012 Jul;107(7):1079–87. [PubMed: 22450732]
108.
Rubin HR, Kahn KL, Rubenstein LV, Sherwood MJ. GuUklinesfar Structured Implicit Review of the Quality of Hospital Care for Diverse Medical and Surgical Conditions. Santa Monica, Calif: RAND; 1990.